# Efinopegdutide Shows Promise in Treating Metabolic Dysfunction-Associated Steatohepatitis Phase 2b trial results indicate significant fibrosis improvement and MASH resolution for patients. - **Source:** [The Lancet – Online First](https://www.thelancet.com) - **Published:** 2026-11-09 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/7c849d84-0b16-4044-ab9b-10c4e2221f1a ## Clinical Trial Overview The phase 2b study evaluated the efficacy and safety of efinopegdutide in adults diagnosed with metabolic dysfunction-associated steatohepatitis and stage 2–3 fibrosis. This randomized, placebo-controlled trial aimed to determine if the once-weekly treatment could effectively resolve MASH without worsening existing liver fibrosis, providing a new therapeutic option for patients. ## Primary Efficacy Results Treatment with efinopegdutide resulted in a significantly greater proportion of participants achieving MASH resolution compared to the placebo group. The study focused on the absence of fibrosis worsening, a critical metric for long-term liver health. These findings suggest that the drug actively addresses the underlying inflammatory processes associated with the condition. ## Optimal Dosage Profile The 7 mg dose demonstrated the most favorable benefit–risk profile among the tested cohorts. Approximately half of the participants receiving this specific dosage experienced an improvement in fibrosis by at least one stage after one year of treatment. This outcome occurred without any concurrent worsening of the underlying steatohepatitis symptoms. ## Mechanism of Action Efinopegdutide functions as a once-weekly GLP-1 and glucagon receptor co-agonist. By targeting these specific receptors, the drug modulates metabolic pathways that contribute to liver fat accumulation and inflammation. This dual-action mechanism is designed to improve metabolic health while simultaneously reducing the structural damage caused by chronic liver disease progression. ## Fibrosis Improvement Metrics The study specifically measured the reduction of fibrosis stages, which is a key indicator of disease reversal. Achieving at least a one-stage improvement is considered a clinically meaningful milestone for patients with stage 2–3 fibrosis. The data confirms that the drug's therapeutic effect is sustained over a full year of administration. ## Safety and Tolerability The trial monitored the safety profile of the drug throughout the 52-week treatment period. By comparing the 7 mg dose against placebo, researchers established that the therapeutic benefits were achieved with a manageable risk profile. This balance is essential for potential long-term use in patients managing chronic metabolic liver conditions. ## Clinical Implications These findings support the potential utility of efinopegdutide as a viable treatment for MASH patients. Given the limited pharmacological options currently available for advanced fibrosis, this co-agonist approach offers a promising pathway. Future research will likely focus on confirming these results in larger, more diverse patient populations to ensure broad applicability. ## Future Research Directions While the phase 2b results are encouraging, further studies are required to fully understand the long-term impact of efinopegdutide on liver health. Researchers will need to evaluate durability of response and potential side effects over extended periods. This study marks a significant step forward in developing targeted therapies for metabolic liver disease. ## Sources covering this story - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02043-X/fulltext?rss=yes — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._